NL
CUE icon

Navalign LLC’s Cue Biopharma CUE Stock Holding History

Navalign LLC’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-833
Closed -$18K – 512
2025
Q3 		$18K Hold
833
– – ﹤0.01% 122
2025
Q2 		$17.1K Hold
833
– – ﹤0.01% 115
2025
Q1 		$22.8K Hold
833
– – 0.01% 114
2024
Q4 		$27.3K Buy
+833
New +$31.3K 0.01% 116
2024
Q3 		– Sell
-833
Closed -$31K – 120
2024
Q2 		$31K Hold
833
– – 0.01% 115
2024
Q1 		$47.3K Hold
833
– – 0.02% 115
2023
Q4 		$66K Buy
+833
New +$59.6K 0.02% 124

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Navalign LLC's CUE Position: Q4 2025 in Review

Navalign LLC sold out of Cue Biopharma (CUE) in Q4 2025, closing a stake of 833 shares — an estimated $18K sold.

Navalign LLC first reported a position in CUE in Q4 2023 and held it in 7 quarters. The position peaked at $66K in Q4 2023. 47 funds tracked by Wall St. Rank hold CUE as of Q4 2025.

  • Navalign LLC reported no remaining Cue Biopharma position as of Q4 2025 after selling out during the quarter.
  • Navalign LLC sold 833 Cue Biopharma shares in Q4 2025, an estimated $18K.
  • Navalign LLC first reported a position in Cue Biopharma in Q4 2023 and held it in 7 quarters.
  • Navalign LLC's Cue Biopharma position peaked at $66K in Q4 2023.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.

Based on Navalign LLC's 13F filing for Q4 2025, filed 5 Feb 2026.